"Such a delight to see a study with treatment naive
"Such a delight to see a study with treatment naive patients instead of salvage work. Treating the newly sick instead of the dying."
Well said my brother! And that could be another paradigm shift in cancer treatment--relegating the use of ICIs (and ADCs etc) to second-third-fourth-line treatment. Courtesy of first-line leronlimab.
I was a little curious, that in this City of Hope study there was no mention of an ICI. I suppose since "treatment naive" implies first-line treatment, the expectation is there will be time for further lines of treatment as necessary. If necessary! I'm actually hopeful for some complete responses in this population... even without an ICI. But will they be durable?
I imagine there are a few things to figure out. Google AI tells us that "chemotherapy can typically increase both CCR5 and PD-L1 in the cancer microenvironment. This increase is often associated with the tumor's mechanism of resistance to therapy and the creation of a more immunosuppressive environment."
Reading further, "T cells in the invasive margins of tumors can produce the CCR5 ligand CCL5, which in turn reprograms tumor associated macrophages to an M2 phenotype, promoting tumor growth." As far as the PD-L1 increase, "One potential mechanism involves the activation of the STING pathway, which can induce CCL5 production and subsequently upregulate PD-L1 expression, contributing to an immunosuppressive TME."
So, chemo kills cancer cells... but also stimulates CCL5 production. Which we know is not good. In fact "Patients with high CCR5 expression on their tumors after receiving chemo tend to have worse outcomes." In the City of Hope trial leronlimab will handle the CCL5/R5 signaling like it always does... But given early as a first-line treatment, will it mitigate the PD-L1 increase that chemo upregulates?
I guess we are going to find out. It gives me great hope that this is an investigator-initiated trial. Nice to have that kind of support that is independent of the company.
And speaking of hope, Hope Rugo left UCSF and is now down south--at City of Hope in LA. She is Director of the Women's Cancers Program there, and Division Chief, Breast Medical Oncology. As well as a Professor of Medical Oncology and Therapeutics. Pretty impressive. Wanna bet she is involved in the mTNBC trial?
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....
Continue Reading
Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...
Continue Reading
A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....
Continue Reading
A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...
Continue Reading
Banking AI has reached the point where a clever chatbot barely moves the needle. Huawei's message at Singapore FinTech Festival 2026 was aimed squarely at that harder, more expensive problem: turning AI from a scattered pilot project into machinery a financial institution can operate, govern, repeat, and improve without handing over its crown jewels. Ownership Is the...
Continue Reading
Concrete Schedules Do Not Bend Easily A jobsite does not care that daycare closes at 6 p.m., and that is exactly why DPR Construction’s latest workplace recognition deserves a closer look. The privately held, employee-owned contractor landed at No. 29 among large companies on the 2026 Fortune Best Workplaces for Parents list. It is not a quarterly earnings event, and...
Continue Reading
Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...
Continue Reading
A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...
Continue Reading
Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...
Continue Reading
Thanksgiving Eve is a peculiar little battlefield for restaurant chains: everybody wants the reunion crowd, nobody wants to give away the register. Chipotle is stepping back into it on Wednesday, November 25, with its Back Home BOGO for Rewards members from 5 to 9 p.m. local time at participating U.S. restaurants. Buy an entrée in person, scan the Rewards account, and...
Continue Reading
Top 5 Most Recently Viewed Articles
Westpac's Urgent Plea for Enhanced Fraud Prevention Westpac Banking Corp's CEO has made a significant call for social media companies, including Meta Platforms, to take a more proactive role in fighting online financial fraud. With an alarming rise in scams targeting consumers, this appeal highlights the urgent need for a united front against fraudulent activities online....
Continue Reading
Empowering Veterans Through Partnership with the Army Today, Bombardier proudly announces its partnership with the U.S. Army via the Partnership for Your Success (PaYS) Program. This initiative is designed to connect service members with valuable civilian career opportunities, ensuring they receive guaranteed job interviews with participating employers. This strategic...
Continue Reading
AWH Stock Experiences Significant Decline AWH stock has recently dropped to a concerning 52-week low of $0.38, reflecting the tough market conditions. The dip in stock price highlights the company’s struggles, with its market capitalization now at a mere $6.5 million. Over the past year, the stock has lost approximately 90.68% of its value, showcasing a substantial...
Continue Reading
Vimeo Posts Third Quarter 2024 Financial Update Vimeo recently shared its financial snapshot for the third quarter of 2024, showcasing the company's growth trajectory and key achievements. The shareholder letter is now available on the investor relations section of their website, allowing stakeholders to delve into the details. This transparency is vital for maintaining...
Continue Reading
Implantica's Year-End Report: Driving Forward with Innovation Implantica has made significant strides in the healthcare sector, particularly with its innovative product, RefluxStop™, which aims to transform how gastroesophageal reflux is treated. This year-end report presents a comprehensive overview of the company's achievements for the year. RefluxStop™ FDA...
Continue Reading